NLRP3 and diabetes mellitus: In a study by Luo et al. using a DCM rat model in the context of experimentally induced type 2 diabetes mellitus, 8 weeks of treatment with rosuvastatin resulted in a decrease in the levels of NLRP3, Asc adaptor, IL-1β, and mitogen-activated protein kinases (MAPKs) in cardiac tissue [136].